Article Text

Download PDFPDF
Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis

Statistics from


  • Contributors All the authors have given substantial contribution to: conception and design, or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be published.

  • Competing interests ICMJE conflicts of interest for each author of this manuscript has been uploaded.

  • Ethics approval Provided by the Ethics committee of Rheumatism Foundation Hospital, Heinola, Finland.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.